Beyond Air^® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

Beyond Air, Inc. announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. to license the commercial rights for multiple nNOS inhibitor candidates, currently being developed for the treatment of autism spectrum disorder and other neurological conditions.